(Q36452714)

14 August 2017

1 reference

title

Current status and perspective of antiangiogenic therapy for cancer: urinary cancer (English)

1 reference

14 August 2017

main subject

angiogenesis inhibitor

1 reference

Shigeru Kanda

1

1 reference

14 August 2017

Yasuyoshi Miyata

series ordinal

2

1 reference

14 August 2017

Hiroshi Kanetake

series ordinal

3

1 reference

14 August 2017

publication date

1 April 2006

1 reference

International Journal of Clinical Oncology

14 August 2017

published in

1 reference

14 August 2017

volume

11

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

90-107

1 reference

The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10147-006-0565-6

Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-006-0565-6

Angiogenesis-targeted therapies in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-006-0565-6

Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-006-0565-6

Copper-induced vascular endothelial growth factor expression and wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-006-0565-6

Malignant breast tumors after radiotherapy for a first cancer during childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-006-0565-6

Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-006-0565-6

Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-006-0565-6

Chemotherapy for metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-006-0565-6

A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma

21 January 2018

1 reference

12 December 2020

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells

1 reference

12 December 2020

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

12 December 2020

Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue

1 reference

12 December 2020

Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma

1 reference

12 December 2020

Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.

1 reference

12 December 2020

Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells

1 reference

12 December 2020

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

12 December 2020

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis

1 reference

12 December 2020

Angiogenesis: role of calcium-mediated signal transduction

1 reference

12 December 2020

Overexpression of hepatocyte growth factor receptor in renal carcinoma cells indirectly stimulates tumor growth in vivo

1 reference

12 December 2020

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.

1 reference

12 December 2020

Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder

1 reference

12 December 2020

Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation

1 reference

12 December 2020

Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma

1 reference

12 December 2020

Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.

1 reference

12 December 2020

Antitumor effect of TNP-470 is not associated to decrease of angiogenesis in an experimental malignant neuroectodermic tumor

1 reference

12 December 2020

Antitumour effect of a synthetic analogue of fumagillin on murine renal carcinoma

1 reference

12 December 2020

Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo.

1 reference

12 December 2020

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

1 reference

12 December 2020

Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study

1 reference

12 December 2020

Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine

1 reference

12 December 2020

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2

1 reference

12 December 2020

Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis

1 reference

12 December 2020

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

12 December 2020

Urinary oxygen pressure in renal parenchymal and vascular disease. Effects of breathing oxygen

1 reference

12 December 2020

Molecular lymphangiogenesis: new players.

1 reference

12 December 2020

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate

1 reference

12 December 2020

Epidermal Growth Factor Receptor mRNA Levels in Human Prostatic Tumors and Cell Lines

1 reference

12 December 2020

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

1 reference

12 December 2020

Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations

1 reference

12 December 2020

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

1 reference

12 December 2020

Discovery of a novel Raf kinase inhibitor

1 reference

12 December 2020

Production of scatter factor by ndk, a strain of epithelial cells, and inhibition of scatter factor activity by suramin

1 reference

12 December 2020

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

1 reference

12 December 2020

Tumor response to radiotherapy regulated by endothelial cell apoptosis

1 reference

12 December 2020

Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder

1 reference

12 December 2020

Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain

1 reference

12 December 2020

The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C.

1 reference

12 December 2020

Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma

1 reference

12 December 2020

FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease

1 reference

12 December 2020

Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3

1 reference

12 December 2020

The expression of basic fibroblast growth factor and vascular endothelial growth factor in prostatic adenocarcinoma: correlation with neovascularization

1 reference

12 December 2020

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

1 reference

12 December 2020

High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma

1 reference

12 December 2020

Copper and calcium binding motifs in the extracellular domains of fibroblast growth factor receptors

1 reference

12 December 2020

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group

1 reference

12 December 2020

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

1 reference

12 December 2020

Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels

1 reference

12 December 2020

Suramin: a novel antineoplastic agent with multiple potential mechanisms of action

1 reference

12 December 2020

Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-density

1 reference

12 December 2020

Gene expression and immunohistochemical localization of basic fibroblast growth factor in renal cell carcinoma

1 reference

12 December 2020

Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1

1 reference

12 December 2020

Signalling hypoxia by HIF hydroxylases

1 reference

12 December 2020

Expression of vascular endothelial growth factor in primary superficial bladder cancer

1 reference

12 December 2020

The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice.

1 reference

12 December 2020

Vascular endothelial growth factor: basic science and clinical progress

1 reference

12 December 2020

Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor

1 reference

12 December 2020

Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells

1 reference

12 December 2020

Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer

1 reference

12 December 2020

Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition.

1 reference

12 December 2020

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

1 reference

12 December 2020

Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2.

1 reference

12 December 2020

The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression

1 reference

12 December 2020

Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival

1 reference

12 December 2020

Phase II evaluation of suramin in advanced renal cell carcinoma. A Southwest Oncology Group study

1 reference

12 December 2020

Copper deficiency as an anti-cancer strategy

1 reference

12 December 2020

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

1 reference

12 December 2020

Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2.

1 reference

12 December 2020

Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

1 reference

12 December 2020

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

12 December 2020

Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide

1 reference

12 December 2020

Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway

1 reference

12 December 2020

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1 reference

12 December 2020

Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines.

1 reference

12 December 2020

Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer

1 reference

12 December 2020

Downmodulation of bFGF-binding protein expression following restoration of p53 function

1 reference

12 December 2020

HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications

1 reference

12 December 2020

Over-expression of fibroblast growth factor-8 in human prostate cancer

1 reference

12 December 2020

The treatment of advanced renal cell cancer with high-dose oral thalidomide

1 reference

12 December 2020

The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression

1 reference

12 December 2020

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

1 reference

12 December 2020

Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder

1 reference

12 December 2020

TNP-470 promotes initial vascular sprouting in xenograft tumors

1 reference

12 December 2020

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

1 reference

12 December 2020

Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.

1 reference

12 December 2020

Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration

1 reference

12 December 2020

Recent advances in angiogenesis, anti-angiogenesis and vascular targeting

1 reference

12 December 2020

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma

1 reference

12 December 2020

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

12 December 2020

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

12 December 2020

A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer

1 reference

12 December 2020

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

1 reference

12 December 2020

Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma

1 reference

12 December 2020

Peritubular endothelial cell proliferation in mice during compensatory renal growth after unilateral nephrectomy

1 reference

12 December 2020

A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis

1 reference

12 December 2020

Cellular signaling by fibroblast growth factor receptors

1 reference

12 December 2020

Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer

1 reference

12 December 2020

Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma

1 reference

12 December 2020

Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets

1 reference

12 December 2020

Suramin treatment in hormone- and chemotherapy-refractory prostate cancer

1 reference

12 December 2020

The angiopoietins and Tie2/Tek: adding to the complexity of cardiovascular development.

1 reference

12 December 2020

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

1 reference

12 December 2020

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

12 December 2020

GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice.

1 reference

12 December 2020

Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma

1 reference

12 December 2020

Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms

1 reference

12 December 2020

Phase II trial of thalidomide in renal-cell carcinoma

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis

1 reference

12 December 2020

Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway

1 reference

12 December 2020

Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival

1 reference

12 December 2020

Angiotensin receptors: a new role in cancer?

1 reference

12 December 2020

Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma

1 reference

12 December 2020

Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin

1 reference

12 December 2020

Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma

1 reference

12 December 2020

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

12 December 2020

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

12 December 2020

Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis

1 reference

12 December 2020

Expression of thrombospondin-derived 4N1K peptide-containing proteins in renal cell carcinoma tissues is associated with a decrease in tumor growth and angiogenesis

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

12 December 2020

FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia

1 reference

12 December 2020

SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.

1 reference

12 December 2020

Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers

1 reference

12 December 2020

Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer

1 reference

12 December 2020

Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects

1 reference

12 December 2020

Regulation of expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cells.

1 reference

12 December 2020

A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma

1 reference

12 December 2020

Tumor-associated endothelial cells with cytogenetic abnormalities.

1 reference

12 December 2020

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

12 December 2020

Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.

1 reference

12 December 2020

Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies

1 reference

12 December 2020

A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Phase II trial of thalidomide for patients with advanced renal cell carcinoma

1 reference

12 December 2020

HIFs, hypoxia, and vascular development

1 reference

12 December 2020

Mitogenic factor in human prostate extracts

1 reference

12 December 2020

VEGF-receptor signal transduction

1 reference

12 December 2020

Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.

1 reference

12 December 2020

Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis

1 reference

12 December 2020

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

1 reference

12 December 2020

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

1 reference

12 December 2020

Inhibition of Hemangiogenesis and LymphangiogenesisafterNormal-Risk Corneal Transplantation by Neutralizing VEGF Promotes Graft Survival

1 reference

12 December 2020

Quantification by competitive quantitative RT-PCR of VEGF121 and VEGF165 in renal cell carcinoma

1 reference

12 December 2020

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

1 reference

12 December 2020

Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer

1 reference

12 December 2020

Thrombospondins 1 and 2 function as inhibitors of angiogenesis

1 reference

12 December 2020

A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder

1 reference

12 December 2020

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

12 December 2020

Targeted agents for the treatment of advanced renal cell carcinoma

1 reference

12 December 2020

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

12 December 2020

Redefining the target: chemotherapeutics as antiangiogenics

1 reference

12 December 2020

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

1 reference

12 December 2020

Complete primary structure of prostatropin, a prostate epithelial cell growth factor

1 reference

12 December 2020

Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder.

1 reference

12 December 2020

Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer

1 reference

12 December 2020

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Angiogenesis in life, disease and medicine

1 reference

12 December 2020

Better survival with interleukin-2-based regimens? Possibly only in highly selected patients.

1 reference

12 December 2020

Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma

1 reference

12 December 2020

Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis

1 reference

12 December 2020

Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas

1 reference

12 December 2020

Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn

1 reference

12 December 2020

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.

1 reference

12 December 2020

Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression

1 reference

12 December 2020

Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth

1 reference

12 December 2020

Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines.

1 reference

12 December 2020

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

12 December 2020

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

1 reference

12 December 2020

aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8

1 reference

12 December 2020

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

Angiogenesis in cancer and other diseases

1 reference

12 December 2020

Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate

1 reference

12 December 2020

Renal Cancer Steroid Receptors: Biochemical Basis for Endocrine Therapy

1 reference

12 December 2020

Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials

1 reference

12 December 2020

Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect.

1 reference

12 December 2020

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression

1 reference

12 December 2020

Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth

1 reference

12 December 2020

Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis

1 reference

12 December 2020

Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer

1 reference

12 December 2020

Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies

1 reference

12 December 2020

Inhibition of angiogenesis in vivo by interleukin 12.

1 reference

12 December 2020

Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder?

1 reference

12 December 2020

Interferons as antiangiogenic agents

1 reference

12 December 2020

A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma

1 reference

12 December 2020

Basic Fibroblast Growth Factor (FGF-2) In Renal Cell Carcinoma, Which is Indistinguishable From that in Normal Kidney, Is Involved in Renal Cell Carcinoma Growth

1 reference

12 December 2020

Cancer therapy: can the challenge be MET?

1 reference

12 December 2020

Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma

1 reference

12 December 2020

Overexpression of the met/HGF receptor in renal cell carcinomas

1 reference

12 December 2020

Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

1 reference

12 December 2020

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma

1 reference

12 December 2020

p63 and p73: roles in development and tumor formation

1 reference

12 December 2020

Recent advances in ideas on the molecular pathology and clinical aspects of Von Hippel-Lindau disease

1 reference

12 December 2020

Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue

1 reference

12 December 2020

Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma

1 reference

12 December 2020

Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer

1 reference

12 December 2020

A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer

1 reference

12 December 2020

Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.

1 reference

12 December 2020

Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D

1 reference

12 December 2020

Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10

1 reference

12 December 2020

Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo

1 reference

12 December 2020

A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial

1 reference

12 December 2020

The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis

1 reference

12 December 2020

A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

1 reference

12 December 2020

Amino-terminal sequence of a large form of basic fibroblast growth factor isolated from human benign prostatic hyperplastic tissue

1 reference

12 December 2020

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

1 reference

12 December 2020

Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors

1 reference

12 December 2020

1 reference

12 December 2020

Alternative splicing of fibroblast growth factor receptors in human prostate cancer

1 reference

12 December 2020

Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma

1 reference

12 December 2020

Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo

1 reference

12 December 2020

Metastatic renal-cell carcinoma: what causes occasional dramatic regressions?

1 reference

12 December 2020

Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.

1 reference

12 December 2020

The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency

1 reference

12 December 2020

Inhibition of angiogenesis by antiestrogens

1 reference

12 December 2020

Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1.

1 reference

12 December 2020

Phase II trial of suramin in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Signals via FGF receptor 2 regulate migration of endothelial cells

1 reference

12 December 2020

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

1 reference

12 December 2020

The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells

1 reference

12 December 2020

Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors

1 reference

12 December 2020

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.

1 reference

12 December 2020

Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.

1 reference

12 December 2020

Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer

1 reference

12 December 2020

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

1 reference

12 December 2020

P53 as a prognostic marker for bladder cancer: a meta-analysis and review.

1 reference

12 December 2020

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

12 December 2020

AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma

1 reference

12 December 2020

Microvessel density in prostatic hyperplasia

1 reference

12 December 2020

Characterization of a heparin-binding growth factor from adenocarcinoma of the kidney

1 reference

12 December 2020

Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study

1 reference

12 December 2020

Fibroblast growth factors, their receptors and signaling

1 reference

12 December 2020

Vascular endothelial growth factor C induces angiogenesis in vivo.

1 reference

12 December 2020

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

1 reference

12 December 2020

Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities

1 reference

12 December 2020

Immunotherapy for advanced renal cell cancer

1 reference

12 December 2020

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma

1 reference

12 December 2020

Different angiogenic pathways characterize superficial and invasive bladder cancer

1 reference

12 December 2020

Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.

1 reference

12 December 2020

Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer

1 reference

12 December 2020

Tumor progression: the effects of thrombospondin-1 and -2.

1 reference

12 December 2020

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

12 December 2020

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

12 December 2020

Fibroblast growth factors

1 reference

12 December 2020

Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression

1 reference

12 December 2020

A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer

1 reference

12 December 2020

c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro.

1 reference

12 December 2020

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

1 reference

12 December 2020

Oxygen tension of the urine and renal structures. Preliminary report of clinical findings

1 reference

12 December 2020

Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470.

1 reference

12 December 2020

Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone

1 reference

12 December 2020

Characterization of the receptors for vascular endothelial growth factor

1 reference

12 December 2020

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha

1 reference

12 December 2020

Signal transduction by fibroblast growth factor receptors

1 reference

12 December 2020

10.1007/S10147-006-0565-6

Identifiers

DOI

1 reference

14 August 2017

1 reference